We are live on
!
Find out more
Cardiff Oncology
CRDF
CRDF
68 hedge funds and large institutions have $12.1M invested in Cardiff Oncology in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
3% more funds holding
Funds holding: 66 → 68 (+2)
0.26% more ownership
Funds ownership: 0% → 0.26% (+0.26%)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
70% less capital invested
Capital invested by funds: $40M → $12.1M (-$28M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $182K
Holders
68
Holders Change
+2
Holders Change %
+3.03%
% of All Funds
1.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
22
Reduced
24
Closed
7
Calls
–
Puts
$182K
Net Calls
-$182K
Net Calls Change
+$447K
Top Buyers
| 1 |
Millennium Management
New York
|
+$895K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$391K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$261K |
| 4 |
Morgan Stanley
New York
|
+$245K |
| 5 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
+$221K |
Top Sellers
| 1 |
BM
Bridger Management
New York
|
-$14.8M |
| 2 |
MWVC
Morgens Waterfall Vintiadis & Co
New York
|
-$1.35M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$705K |
| 4 |
Goldman Sachs
New York
|
-$237K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$220K |
